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phospholipase D (NAPE-PLD) and diacylglycerol lipase (DAGL) 
accelerated molecular biological studies on the eCB biosyntheses 
(Bisogno et al., 2003; Okamoto et al., 2004). eCBs are synthesized 
“on demand” at the post-synaptic sites of neurons after an increase 
in neural activity and calcium ion influx, and are then released 
into the synaptic cleft. Their main function appears to be the sup-
pression of neurotransmitter release from the presynapse. Thus, 
eCBs act as retrograde neurotransmitters, modulating other neu-
rotransmitter systems.
CB1 and CB2 are metabotropic receptors coupled to G-proteins 
of the Gi/o type. CB1 receptors are localized mainly in the cen-
tral nervous system, but are also present in a variety of peripheral 
tissues; they are among the most abundant and widely distrib-
uted G-protein coupled receptors in the brain. CB1 receptors are 
expressed in multiple brain areas, including the olfactory bulb, 
neocortex, pyriform cortex, hippocampus, amygdala, basal ganglia, 
thalamic and hypothalamic nuclei, cerebellar cortex, and brainstem 
nuclei (Herkenham et al., 1990, 1991; Katona et al., 2001). CB2 
receptors are mostly peripherally located on immunological tissues, 
but they have also been found within the central nervous system 
on neurons and glial cells with their expression mainly related to 
conditions of inflammation (Galiegue et al., 1995; Schat et al., 1997; 
Begg et al., 2005). More recent immunohistochemical analyses have 
revealed the presence of CB2 receptors in apparently neuronal and 
glial processes in diverse rat brain areas, including the cerebellum 
and hippocampus (Van Sickle et al., 2005; Onaivi et al., 2006).
IntroductIon
Considerable evidence suggests that cannabinoids impair hip-
pocampal-dependent learning and memory processes, such as 
spatial learning and context-related memory tasks (Sullivan, 2000; 
Riedel and Davies, 2005). In this review, I will provide evidence that 
suggests that the effects of cannabinoids on memory and plasticity 
are complex and depend on several factors, such as the nature of 
the task (emotional or non-emotional), the memory stage investi-
gated (acquisition, retrieval, and extinction), and the experimental 
model used. Naturally, the behavioral effects of cannabinoids on 
memory may vary as a function of dose, route of administration, 
and the specific drug used.
cannabInoId receptors In the hIppocampus
Cannabis has a long history of consumption both for recreational 
and medicinal uses. The main psychoactive constituent of mari-
juana, delta-9-tetrahydrocannabinol (THC), was identified in 1964 
(Gaoni and Mechoulam, 1964) and this discovery led to the iden-
tification of the endogenous endocannabinoid (eCB) system. This 
system includes cannabinoid receptors (CB1 and CB2), eCBs [anan-
damide and 2-arachidonoyl-glycerol (2-AG)], enzymes involved in 
their synthesis and metabolism [fatty acid amide hydrolase (FAAH) 
for anandamide and the monoacylglycerol lipase (MAGL) for 
2-AG], and an eCB transporter (Devane et al., 1992; Freund et al., 
2003; Kogan and Mechoulam, 2006). Recent cDNA cloning of the 
key enzymes such as N-acylphosphatidylethanolamine-hydrolyzing 
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doi: 10.3389/fnbeh.2011.00034In the hippocampus, CB1 receptors are expressed at an espe-
cially high density in the dentate gyrus, CA1, and CA3 regions 
(Herkenham et al., 1990, 1991; Matsuda et al., 1990; Tsou et al., 
1998). CB1 receptors are predominantly localized on the axon 
terminals and preterminal segments of cholecystokinin (CCK)-
expressing GABAergic interneurons (Nyíri et al., 2005); however, 
they have also been demonstrated to inhibit glutamatergic transmis-
sion in cultured hippocampal cells (Shen, et al., 1996). CB1 recep-
tors located on GABAergic axon terminals are activated by lower 
concentrations of cannabinoid receptor agonists than CB1 receptors 
located on glutamatergic terminals (Ohno-Shosaku et al., 2001; 
Hoffman et al., 2007) and CB1 receptor expression is significantly 
lower on glutamatergic terminals than on GABA axon terminals 
in the hippocampus (Katona et al., 2006; Kawamura et al., 2006). 
Specifically, activation of hippocampal CB1 receptors decreases 
GABA release (Katona et al., 1999; Hajos et al., 2000; Hoffman and 
Lupica, 2000; Hoffman et al., 2003). The CB1-containing GABergic 
interneurons are thought to control oscillatory electrical activity 
in the hippocampus in the theta and gamma frequencies, which 
plays a role in synchronizing pyramidal cell activity (Hoffman and 
Lupica, 2000).
Overall, the evidence favors a predominant role for GABAergic 
pathways in the effects of cannabinoids on hippocampal-dependent 
memory processes.
cannabInoId agonIsts ImpaIr hIppocampal-
dependent learnIng and memory
In humans, non-human primates, and rodents, cannabinoids 
impair the performance of a wide variety of memory tasks that 
share the common feature of requiring the hippocampus for nor-
mal performance (Sullivan, 2000; Davies et al., 2002; Riedel and 
Davies, 2005). In laboratory rodents, activation of cannabinoid 
receptors via THC or synthetic analogues such as WIN 55,212-2, 
CP55940, HU-210 or the endogenous agonist anandamide impairs 
learning (Davies et al., 2002). Administration of THC disrupts 
hippocampal-dependent learned behavior in operant and spatial 
maze models of memory (Nakamura et al., 1991; Heyser et al., 1993; 
Lichtman et al., 1995; Brodkin and Moerschbaecher, 1997; Mallet 
and Beninger, 1998; Ferrari et al., 1999; Varvel et al., 2001). For 
example, systemic THC administration (2–6 mg/kg i.p.) impairs 
working memory tested in the radial-arm spatial task and the 
cannabinoid antagonist SR141716A (1–10 mg/kg) prevents these 
deficits in a dose-dependent manner (Lichtman and Martin, 1996). 
Similarly, THC (8 mg/kg) impairs the acquisition of spatial learn-
ing in the water maze and the performance of mice in a working 
memory task, while consolidation and retrieval of a previously 
learned task are not affected. Pre-treatment with the antagonist 
SR 141716A (1 mg/kg i.p.) prevents these learning deficits (Da and 
Takahashi, 2002). Additionally, systemic administration of THC or 
the synthetic cannabinoid receptor agonist WIN 55,212-2 reliably 
impairs performance in delayed-match-to-sample and delayed-
non-match-to-sample tasks, and this is accompanied by decreases 
in hippocampal cell firing during the sample phases of the task 
(Heyser et al., 1993; Hampson and Deadwyler, 1999, 2000).
Overall, the literature discussed above suggests that activation 
of cannabinoid receptors impairs learning. However, since the ago-
nists were systemically infused, most of these experiments do not 
specifically show that cannabinoids impair learning and memory 
via action on the hippocampus. Rather, the involvement of the hip-
pocampus is assumed because it is an important target for systemi-
cally administered cannabinoids and because most of the paradigms 
described are spatial tasks known to be hippocampus-dependent.
More recent research has directly tested whether specific admin-
istration of cannabinoids into the hippocampus would have similar 
effects (summarized in Table 1). Intrahippocampal infusions of 
the agonists CP55940, THC, or WIN 55,212-2 were found to dis-
rupt performance in the radial-arm maze, and in T-maze delayed 
alternation, passive avoidance, spatial learning, and place recogni-
tion memory tasks (Lichtman et al., 1995; Mishima et al., 2001; 
Egashira et al., 2002; Suenaga and Ichitani, 2008; Suenaga et al., 
2008; Wegener et al., 2008; Abush and Akirav, 2010). For example, 
activation of hippocampal cannabinoid receptors by the agonist 
WIN 55,212-2 (1–2 μg) dose-dependently decreases the explora-
tion of an object in a new place, and this effect is antagonized by 
pre-treatment with the cannabinoid receptor antagonist AM 281 
(2 mg/kg, i.p.; Suenaga and Ichitani, 2008). WIN 55,212-2 (5 μg) 
injected into the dorsal hippocampus increases the number of 
reference memory errors in the eight-arm radial-maze task, sug-
gesting impairment of memory retrieval (Wegener et al., 2008). 
Additionally, post-training intrahippocampal administration of 
WIN 55,212-2 (2.5 and 5 μg) disrupts long-term spatial mem-
ory, but not acquisition or short-term memory, in a rat reference 
memory task in the water maze (Yim et al., 2008). We have recently 
found that WIN 55,212-2 administered systemically (0.5 mg/kg) 
or specifically into the hippocampal CA1 area (5 μg/side) before 
massed training in the Morris water maze impairs spatial learn-
ing (Abush and Akirav, 2010). Thus experiments that specifically 
targeted the hippocampus confirm the implications of the earlier 
systemic research as to the impairing effect of cannabinoids on 
hippocampal-dependent learning and memory.
cannabInoId agonIsts ImpaIr hIppocampal synaptIc 
plastIcIty
In neuronal circuits, memory storage depends on activity-
dependent modifications in synaptic efficacy, such as long-term 
potentiation (LTP) and long-term depression (LTD), which are 
Table 1 | Effects of intra-dorsal hippocampal WIN 55,212-2 on learning and memory.
Doses (μg)  Task  Memory stage  Effects  References
1–2  Place recognition  Short-term retrieval  Impair  Suenaga and Ichitani (2008)
5  Radial-maze  Long-term retrieval  Impair  Wegener et al. (2008)
2.5 and 5  Spatial (water maze)  Long-term retrieval  Impair  Yim et al. (2008)
5  Spatial (water maze)  Acquisition Impair  Abush and Akirav (2010)
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sus slices, or from various methodological issues, such as different 
stimulation protocols, different drug doses, etc.
effects of cannabInoId agonIsts on emotIonal and 
non-emotIonal memory
Although considerable evidence suggests that activation of CB1 
receptors can induce learning and memory impairments (Sullivan, 
2000; Robinson et al., 2003; O’Shea et al., 2004; Varvel et al., 2005), 
CB1 receptors are essential for the extinction of conditioned fear 
associations (Marsicano et al., 2002), indicating an important role 
for this receptor in neuronal emotional learning and memory.
role of the cannabInoId system In extInctIon
Extinction was established as a tool to treat conditioned fear by 
Freud in the 1920s. It has become widely accepted that a deficit in 
the capacity to extinguish memories of fear is at the root of fear 
disorders as a result of the distinction between those who do and do 
not develop serious symptoms after fearsome experiences, and the 
fact that fear disorders are treated with therapy based on extinction 
procedures. Moreover, panic attacks, phobias, and particularly post-
traumatic stress disorder (PTSD) are viewed by many as a deficit 
of extinction that should therefore be treated by an intensification 
of extinction (Charney et al., 1993; Wessa and Flor, 2007; Milad 
et al., 2008).
Conditioned fear is induced by pairing a neutral, conditioned 
stimulus (CS; e.g., a light, a tone, or a context) with an aversive 
stimulus (unconditioned stimulus, US; e.g., a mild footshock) that 
evokes a measurable fear response. Experimental extinction learn-
ing occurs when a CS that previously predicted a US no longer 
does so, and over time, the conditioned response (e.g., freezing or 
elevated skin conductance responses) decreases. Extinction learn-
ing involves the ventromedial prefrontal cortex (PFC), amygdala, 
and hippocampus (Milad and Quirk, 2002; Phelps et al., 2004; 
Bouton et al., 2006). PTSD patients continue to re-experience the 
traumatic event over a long timeframe and avoid trauma-related 
stimuli, even though they recognize that the traumatic event is 
no longer occurring. It has been suggested that dysfunctional fear 
extinction plays an important role in the development of clinical 
symptoms, such as reexperiencing trauma in PTSD (Rothbaum 
and Davis, 2003; Milad et al., 2006; Quirk et al., 2006; Rauch et al., 
2006). PTSD patients also demonstrate impaired extinction in the 
aftermath of new trauma. For example, Milad et al. (2008) have 
shown deficient extinction recall as measured in skin conductance 
response in a 2-day fear conditioning and extinction procedure in 
PTSD patients.
Clearly, animal models do not entirely mimic the complex 
features of psychiatric disorders. However, they can predict the 
clinical effects of substances and provide insights into the biologi-
cal mechanisms of these diseases. Marsicano et al. (2002) found 
that CB1 receptor-deficient mice show normal acquisition and 
consolidation in a fear conditioning task, but fear extinction is 
strongly impaired. Impaired extinction is also observed when the 
antagonist SR141716 is injected systemically into wild-type mice 
before the extinction trial, indicating that CB1 receptors are required 
at the moment of the extinction training. The findings that CB1 
knockout mice exhibit impaired short- and long-term extinction 
the two main forms of synaptic plasticity in the brain. A key 
feature of LTP and LTD is that a short period of synaptic activity 
(either high- or low-frequency stimulation) can trigger persistent 
changes in synaptic transmission lasting at least several hours 
and often longer. This single property initially led investigators 
to suggest that these forms of plasticity are the cellular correlate 
of learning (Bliss and Gardner-Medwin, 1973; Bliss and Lomo, 
1973). Indeed, efforts to understand synaptic plasticity are driven 
by the belief that such synaptic modifications might occur during 
learning and memory. However, it is extremely difficult to dem-
onstrate directly that learning-induced synaptic changes occur 
following experience.
The mechanisms underlying synaptic plasticity have been stud-
ied more intensely in the hippocampus than in any other brain 
region. Both forms of synaptic plasticity have been studied most 
intensively at the Schaffer collateral–CA1 synapses of the hip-
pocampus because of the established role of the CA1 area in spa-
tial memory (Behr et al., 2009). LTP and LTD are thought to be 
involved in memory formation at glutamatergic synapses in the 
hippocampus. Cannabinoids appear to work by reducing glutamate 
release below the level needed to activate N-Methyl-d-aspartate 
(NMDA) receptors that are required for LTP and LTD (Shen et al., 
1996; Misner and Sullivan, 1999). CB1 receptors are capable of 
regulating both inhibitory and excitatory neurotransmitter release 
in the hippocampus and are thus capable of exerting subtle control 
over synaptic plasticity.
Most of our knowledge about cannabinoids and activity- 
dependent changes in synaptic strength comes from studies per-
formed at excitatory synapses, largely using acute hippocampal slices 
as the experimental model (Chevaleyre et al., 2006). Cannabinoid 
receptor activation inhibits both LTP and LTD induction in the 
hippocampal slice. The inhibition of LTP in field potentials in the 
CA1 region has been demonstrated using THC, HU-210, WIN 
55,212-2, 2-AG, and anandamide (Nowicky et al., 1987; Collins 
et al., 1994, 1995; Terranova et al., 1995; Misner and Sullivan, 1999) 
and has been found recently to inhibit hippocampal LTD of CA1 
field potentials as well (Misner and Sullivan, 1999). The impair-
ment in the induction of LTP in the CA1 is blocked by cannabinoid 
antagonists such as SR141716A.
We have recently examined cannabinoid modulation of LTP 
and LTD in a different experimental model: acute anesthetized rats. 
Using this experimental condition, we found that i.p. administra-
tion of WIN 55,212-2 or the CB1 receptor antagonist AM251 at the 
doses tested impairs LTP in the Schaffer collateral–CA1 projection, 
with no effect on LTD (Abush and Akirav, 2010; see Figure 1).
de Oliveira Alvares et al. (2006) have also demonstrated impair-
ment of LTP in a CA1 slice preparation following AM251 adminis-
tration. Sokal et al. (2008) found that the CB1 receptor antagonist 
SR141716A blocked the potentiation of the fEPSP slope observed 
following HFS to the perforant path. However, other studies 
conducted on hippocampal slices of the Schaffer collateral–CA1 
synapses have shown that CB1 blockade favors LTP in the hip-
pocampus (Slanina et al., 2005) and that mice lacking CB1 recep-
tors show enhanced LTP (Bohme et al., 2000). However, in the 
study by Slanina et al. (2005), the drug was present throughout the 
experiment and LTP was elicited by moderate stimulations (20 or 
50 pulses). Thus, the discrepancies with our findings could result 
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and intracerebroventricular (Bitencourt et al., 2008) injections. In 
another study (Varvel et al., 2007), OL-135 (30 mg/kg), an inhibi-
tor of FAAH, enhanced the rate of extinction in a water maze task. 
Pamplona et al. (2006) showed that WIN 55,212-2 (0.25 mg/kg) 
facilitates the extinction of contextual fear in the fear conditioning 
task and of spatial memory in the water maze reversal task. We have 
used the light–dark inhibitory avoidance procedure to demonstrate 
the effects of WIN 55,212-2 administered into the CA1 or the BLA 
on extinction. This procedure is dependent on both the amygdala 
and hippocampus as a single CS–US (context–footshock) pairing 
establishes a robust long-term memory, expressed as an increase in 
latency to enter the dark chamber at testing. Repeated retrieval of 
the avoidance response in the absence of the US induces extinction 
of inhibitory avoidance memory, meaning that the animal learns 
of  cue-induced conditioned fear responses have been replicated by 
other groups for the extinction of both cue- and context-induced 
fear responses (Finn et al., 2004; Suzuki et al., 2004; Chhatwal et al., 
2005; Lafene ˆtre et al., 2007; Lutz, 2007; Niyuhire et al., 2007). We 
have recently shown that microinjecting the antagonist AM251 
(6 ng) into the BLA or the CA1 significantly impairs extinction of 
inhibitory avoidance (Ganon-Elazar and Akirav, 2009; Abush and 
Akirav, 2010). Several studies suggest that the eCB system is not 
involved in the extinction of non-aversive memories (Hölter et al., 
2005; Niyuhire et al., 2007).
On the other hand, studies have demonstrated that pharma-
cological activation of eCB signaling promotes extinction of fear 
memories. For example, Chhatwal et al. (2005) found that systemic 
administration of the eCB transporter AM404 (10 mg/kg) pro-
motes extinction of fear that was conditioned using fear-potentiated 
FIguRE 1 | CB1 receptor antagonist and agonist impair the induction of LTP . (A) 
AM251 injected i.p. (1 or 2 mg/kg) 30 min before application of high frequency 
stimulation (HFS; 200 Hz) to the Schaffer collateral significantly impairs the induction 
of LTP in the CA1 compared with the vehicle group (P < 0.01, vehicle differs from all 
the groups). No significant difference is observed between the groups before HFS. 
(B) WIN 55,212-2 (0.5 mg/kg) injected i.p. 20 min before application of HFS (200 Hz) 
to the Schaffer collateral significantly impairs the induction of LTP in the CA1 
compared with the vehicle group (P < 0.01). No significant difference is observed 
between the groups before HFS. Inset: representative traces in the CA1 for vehicle 
(upper traces) and WIN 0.5 mg (lower traces) groups taken before (black) and 90 min 
after (gray) HFS to the Schaffer collateral (calibration: 0.2 mV, 10 μs). Data published 
by Abush and Akirav (2010) in Hippocampus.
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may have different outcomes depending on task aversiveness and 
the brain region involved (Suzuki et al., 2004; de Oliveira Alvares 
et al., 2005; Varvel et al., 2005; Ganon-Elazar and Akirav, 2009; 
Abush and Akirav, 2010).
effects of cannabInoIds on stress and anxIety
Considerable evidence suggests that cannabinoids are anxiolytics 
and modulate the behavioral and physiological response to stress-
ful events (Viveros et al., 2007; Hill et al., 2010). Consequently, the 
effects of CB1 agonists on learning and memory may be attribut-
able to a general modulation of anxiety or stress levels and not to 
memory per se.
Stress is most readily defined as any stimulus that presents a 
challenge to homeostasis including any actual or potential distur-
bance of an individual’s environment. The stress response enables 
the animal to adapt to the changing environment (Joëls and Baram, 
2009). Fear is an adaptive component of the acute stress response to 
potentially dangerous stimuli that threaten the integrity of the indi-
vidual. However, when disproportionate in its intensity, chronic, 
irreversible, and/or not associated with any actual risk, it constitutes 
a maladaptive response and may be symptomatic of anxiety-related 
neuropsychiatric disorders (Taber and Hurley, 2009).
Anxiety disorders are marked by excessive fear (and avoidance), 
often in response to specific objects or situations, in the absence 
of true danger, and they are common in the general population 
(Shin and Liberzon, 2010). As excessive fear is a key component 
of anxiety disorders, the search for the neurocircuitry of anxiety 
disorders has focused extensively on studies of fear circuits in ani-
mal models. These studies examined the neurocircuitry associated 
with fear responses in rats and mice using fear conditioning para-
digms, inhibitory avoidance, and fear-potentiated startle models. 
The amygdala, PFC, and hippocampus have arisen as clear regions 
of interest in studies of anxiety disorders and are implicated in 
PTSD (Shin and Liberzon, 2010).
The hippocampus is often implicated in the neurobiology of 
stress. Mineralocorticoid and glucocorticoid receptors are expressed 
in high numbers within the hippocampus. Although stress-induced 
corticosteroid signaling in the hippocampus has a beneficial role in 
regulating the time course of the hypothalamic–pituitary–adrenal 
(HPA) axis stress response (De Kloet et al., 2005), prolonged gluco-
corticoid signaling can damage the hippocampus as measured by 
dendritic atrophy, decreased neurogenesis, and deficits in synap-
tic plasticity (McEwen and Gould, 1990; Sapolsky, 1996; McEwen, 
1999; Meaney, 2001). In PTSD and major depression patients, hip-
pocampus volumes are reduced (Bremner et al., 1995; Sheline et al., 
1999; Woon and Hedges, 2008), and smaller hippocampal volumes 
are predictive of vulnerability to developing stress-related disorders 
(Pitman et al., 2006).
role of the endocannabInoId system In uncondItIoned stress 
and anxIety
Results from many studies indicate that the eCB system modulates 
unconditioned stress- and anxiety-like responses (Viveros et al., 
2005; Gorzalka et al., 2008; Lutz, 2009). A general conclusion that 
can be tentatively derived from the complicated and often contra-
dictory literature is that inhibition of eCB signaling increases stress 
that the context no longer predicts the footshock. We found that 
WIN 55,212-2 administered into the CA1 facilitates the extinction 
of inhibitory avoidance, with no effect on extinction kinetics when 
microinjected into the BLA (Ganon-Elazar and Akirav, 2009; Abush 
and Akirav, 2010).
Hence, the results of Marsicano et al. (2002) and subsequent 
investigations demonstrate that inhibition of eCB transmission 
robustly inhibits (or prolongs) fear extinction (Suzuki et al., 2004; 
Pamplona et al., 2006; Ganon-Elazar and Akirav, 2009; Abush and 
Akirav, 2010). Conversely, stimulation of eCB transmission acceler-
ates fear extinction (Suzuki et al., 2004; Chhatwal et al., 2005; Barad 
et al., 2006; Abush and Akirav, 2010).
comparIng the effects of cannabInoId agonIsts on aversIve 
and non-aversIve tasks
It has been suggested that the neural processes underlying emo-
tional memory formation (such as extinction learning) and non-
emotional memories (such as spatial learning) are differentially 
sensitive to cannabinoid receptor activation (Chhatwal and Ressler, 
2007). An intriguing question is whether cannabinoids have a simi-
lar effect on other types of emotional memories that do not involve 
fear and extinction learning.
We have recent findings suggesting that cannabinoid receptor 
activation has differential effects on learning and memory that 
are task-, brain region-, and memory stage-dependent (Segev and 
Akirav, 2011). We examined the effects of WIN 55,212-2 micro-
injected into the amygdala and the subiculum on the acquisition 
and retrieval of a neutral learning task (i.e., social discrimination) 
and an aversive learning task (i.e., contextual fear conditioning). 
The subiculum is the principal target of CA1 pyramidal cells. It 
functions as a mediator of hippocampal–cortical interaction and 
has been proposed to play an important role in the encoding and 
retrieval of long-term memory. In fear conditioning paradigms, 
the BLA plays a central role in the formation and consolidation 
of fear-related memory traces (LeDoux, 2003; Maren and Quirk, 
2004), whereas the hippocampus’s role is to integrate the features of 
the context and not to form a context–shock association (Fanselow, 
1998). Unlike the aversive fear conditioning task, social discrimi-
nation is considered neutral or even rewarding. This finding was 
established using both conditioned place preference paradigms and 
T-maze learning rewarded by social interaction (Van den Berg et al., 
1999). Social recognition processes depend on brain regions such as 
the medial amygdala, which modulates the initial social encounter 
and formation of social memory (Ferguson et al., 2001; Bielsky 
and Young, 2004) and the ventral hippocampus (Van Wimersma 
Greidanus and Maigret, 1996; Kogan et al., 2000).
We found that in the aversive contextual fear task, WIN 
55,212-2 administered into the BLA impairs fear acquisition/
consolidation, but not retrieval, whereas in the ventral subiculum 
(vSub), WIN 55,212-2 impairs fear retrieval. In the non-aversive 
or rewarding social discrimination task, WIN 55,212-2 into the 
vSub impairs acquisition/consolidation and retrieval, whereas in 
the medial amygdala, WIN 55,212-2 impairs acquisition (Segev 
and Akirav, 2011). These findings suggest that cannabinoid ago-
nists can impair emotional (or aversive) as well as neutral (or 
rewarding) memory-related processes in a task-, region-, and 
memory stage-dependent manner. This is consistent with other 
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THC induces increased aversion to the open arms of the EPM 
in both rats and mice that is similar to the aversion produced 
by anxiogenic agents. In contrast, mice treated with the agonists 
cannabidiol and nabilone spend a greater amount of time in the 
open arms of the maze, an effect similar to that produced by 
diazepam, the reference anxiolytic agent.
In the light–dark box, Berrendero and Maldonado (2002) have 
shown that the systemic administration of a low dose of THC 
(0.3 mg/kg) produces clear anxiolytic-like responses. The CB1 
cannabinoid receptor antagonist SR 141716A (0.5 mg/kg) com-
pletely blocks the anxiolytic-like response induced by THC, sug-
gesting that this effect is mediated by CB1 cannabinoid receptors. 
In another study, systemic administration of the FAAH inhibitors 
URB597 and URB532 reduces anxiety-related behavior in the rat 
elevated zero-maze and in isolation-induced ultrasonic vocaliza-
tion tests (Kathuria et al., 2003). These effects are dose-dependent 
and blocked by the antagonist rimonabant. The FAAH inhibitor 
and eCB re-uptake inhibitor AM404 also exhibit a dose-depend-
ent anxiolytic profile in the EPM, defensive withdrawal test, and 
ultrasonic vocalization test (Bortolato et al., 2006). URB597 has 
also been shown to be anxiolytic in the rat EPM and open-field 
tests (Hill et al., 2007) and has recently been shown to reduce 
anxiety-related behavior in the EPM in Syrian hamsters (Moise 
et al., 2008).
Ribeiro et al. (2009) examined the dose-response effects of exog-
enous anandamide at doses of 0.01, 0.1, and 1.0 mg/kg in mice 
sequentially submitted to the open field and EPM. Systemically 
administered at 0.1 mg/kg (but not at 0.01 or 1 mg/kg), anandamide 
increases the time spent and the distance covered in the central zone 
of the open field, as well as exploration of the open arms of the EPM. 
Recently, Rubino et al. (2008b) demonstrated that the anxiolytic-
like effect of a low anandamide dose is reversed by administration 
of the antagonist AM251, whereas the anxiogenic-like effect is 
and anxiety, while moderate increases in eCB signaling decrease 
stress and anxiety (Lutz, 2009; summarized in Table 2). The term 
“moderate” is used because strong stimulation of eCB signaling by 
high doses of CB1 receptor agonists potentiates stress- and anxiety-
like responses (Rodriguez de Fonseca et al., 1996; Scherma et al., 
2008; Lutz, 2009). This biphasic effect has been demonstrated in 
animal models of anxiety (Lafene ˆtre et al., 2007; Hill and Gorzalka, 
2009), and also in humans. Cannabis may induce aversive states in 
some smokers, precipitating anxiety and panic attacks (Hall and 
Solowij, 1998). Furthermore, THC administration may result in 
psychotic-like states (Linszen and van Amelsvoort, 2007). These 
bidirectional effects of cannabinoids observed in humans can be 
mimicked in laboratory animals. Hence, in models predictive of 
anxiolytic-like activity, low doses of CB1 agonists tend to be anxio-
lytic and high doses tend to increase aversion and anxiety-related 
behaviors (Viveros et al., 2005).
Procedures used in studies on the role of eCBs in stress and 
anxiety evaluate the anxiolytic/anxiogenic effects of drugs by 
using standard tasks such as the elevated plus maze (EPM), 
social interaction, and defensive burying (Viveros et al., 2005; 
Lutz, 2009). Using the EPM, Patel and Hillard (2006) found that 
cannabinoid receptor agonists WIN 55212-2 (0.3–10 mg/kg) and 
CP55940 (0.001–0.3 mg/kg) administered systemically increase 
the time mice spend on the open arms (i.e., elicit an anxiolytic 
response) only at low doses. At the highest doses, both compounds 
alter overall locomotor activity. In contrast, THC (0.25–10 mg/kg) 
produces a dose-dependent reduction in time spent on open arms. 
The eCB uptake/catabolism inhibitor AM404 (0.3–10 mg/kg) pro-
duces an increase in time spent on the open arms at low doses 
and has no effect at the highest dose tested. The FAAH inhibitor 
URB597 (0.03–0.3 mg/kg) produces a monophasic, dose-depend-
ent increase in time spent on the open arms. Systemic admin-
istration of the CB1 receptor antagonists SR141716 (1–10 mg/
kg) and AM251 (1–10 mg/kg) produce dose-related decreases in 
Table 2 | Effects of cannabinoids on anxiety-related responses.
Agonist  Species Doses  Apparatus  Effects References
WIN 55,212-2  Mice  0.3–10 mg/kg  EPM  +  Patel and Hillard (2006)
CP55940  Mice  0.001–0.3 mg/kg  EPM  +  Patel and Hillard (2006)
THC  Mice  0.25–10 mg/kg  EPM  −  Patel and Hillard (2006)
  Rats  1–10 mg/kg  EPM  −  Onaivi et al. (1990)
  Mice  10–20 mg/kg   EPM  −  Onaivi et al. (1990)
  Mice  0.3 mg/kg  Light–dark box  +  Berrendero and Maldonado (2002)
AM404  Mice  0.3–10 mg/kg  EPM  +  Patel and Hillard (2006)
URB597  Mice  0.03–0.3 mg/kg  EPM  +  Patel and Hillard (2006)
  Rats  0.05–0.1 mg/kg  Zero-maze  +  Kathuria et al. (2003)
      Ultrasonic test  +  Kathuria et al. (2003)
URB532  Rats  0.1–10 mg/kg  Zero-maze  +  Kathuria et al. (2003)
      Ultrasonic test  + 
Nabilone  Mice  10–100 μg/kg  EPM  +  Onaivi et al. (1990)
Cannabidiol  Mice  1–10 mg/kg  EPM  +  Onaivi et al. (1990)
Anandamide  Mice  0.1 mg/kg  EPM  +  Ribeiro et al. (2009)
      Open field  + 
Effects: −, anxiogenic effect; +, anxiolytic effect. EPM, elevated plus maze.
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Overall it appears that, as in the case of unconditioned fear, inhibi-
tion of eCB transmission increases fear while moderate stimulation 
of eCB transmission decreases fear.
the Involvement of the hIppocampus In endocannabInoId 
modulatIon of stress and anxIety
Techniques based on intracranial injections of cannabinoids 
in rats revealed that activation of CB1 receptors is involved in 
inducing anxiolytic- or antidepressant-like effects (Bambico et al., 
2007; Moreira et al., 2007; Rubino et al., 2008a,b). For example, 
Rubino et al. (2008a) found that low doses of THC microin-
jected into the PFC (10 μg) or ventral hippocampus (5 μg) in 
rats induces an anxiolytic-like response during tests in the EPM, 
while higher doses do not show an anxiolytic effect and even seem 
to switch into an anxiogenic profile. Nevertheless, other studies 
demonstrated that eCB activation in the amygdala and dorsal 
hippocampus results in an anxiogenic-like response. Low THC 
doses (1 μg) in the BLA produce an anxiogenic-like response 
whereas higher doses are ineffective (Rubino et al., 2008a). WIN-
55212-2 in the dorsal hippocampus (2.5 and 5 μg) produces a 
significant anxiogenic-like effect in rats that is reversed by AM251 
(Roohbakhsh et al., 2007).
Local infusion of cannabinoid compounds into specific brain 
areas might be instrumental in identifying neural pathways and 
neuroanatomically separated CB1 receptor subpopulations that may 
play distinct roles in and mediate the opposing actions of cannabi-
noids, notably, anxiolytic versus anxiogenic effects (Moreira et al., 
2007; Viveros et al., 2007). We examined the role of cannabinoids 
in modulating aversive and non-aversive learning paradigms in 
the hippocampus and amygdala (Ganon-Elazar and Akirav, 2009; 
Abush and Akirav, 2010; Segev and Akirav, 2011). Microinjecting 
the antagonist AM251 (6 ng) or the agonist WIN-55212-2 (5 μg) 
into the BLA, CA1, or vSub had no effect on anxiety levels as meas-
ured in the open-field, pain sensitivity (Ganon-Elazar and Akirav, 
2009; Abush and Akirav, 2010; Segev and Akirav, 2011), or EPM tests 
(Abush and Akirav, 2010). However, both agonist and antagonist 
had profound effects on aversive and non-aversive learning tasks. 
These findings suggest that in these studies the impairing and facili-
tating effects of local infusions of WIN-55212-2 on learning and 
memory are probably not attributable to a general modulation of 
anxiety. Nevertheless, the effects of cannabinoids on the interplay 
between anxiety and memory processes are difficult to separate 
and further examination of the effects of different cannabinoids 
is required.
To summarize the role of the eCB system in stress, anxiety, and 
conditioned fear, there is a general consensus that the effects of 
cannabinoid agonists on anxiety seem to be biphasic, with low 
doses being anxiolytic and high doses being ineffective or possibly 
anxiogenic. There are several important characteristics of the eCB 
system that might explain these different effects of eCB modula-
tion. First, in a physiological situation, eCB synthesis, and thus 
CB1 receptor activation, occurs in particular activated neuronal 
circuits. This is a notable difference from the situation following 
pharmacological treatment with receptor agonists, when the agent 
activates all CB1 receptors in the brain regardless of their specific 
involvement in a particular physiological process. Second, the CB1 
inhibited by pre-treatment with capsazepine, a transient recep-
tor potential vanilloid type 1 (TRPV1) receptor antagonist. The 
authors suggested that the anxiolytic effect evoked by anandamide 
might be due to the interaction with the CB1 cannabinoid receptor, 
whereas vanilloid receptors seem to be involved in the anxiogenic 
action of anandamide (Rubino et al., 2008b). Marsch et al. (2007) 
reported that TRPV1 “null” mice exhibit a significantly reduced 
response to anxiogenic stimuli. Therefore, the anandamide-induced 
inverted U-shape pattern might be based on the fact that the intrin-
sic efficacy of anandamide on TRPV1 is relatively low compared 
to that observed on the CB1 receptor (Ross, 2003).
Transgenic mice deficient for FAAH, the enzyme that degrades 
anandamide, demonstrate reduced anxiety-like behavior in the 
EPM and light–dark box compared with wild-type mice and these 
effects are prevented by systemic administration of the antagonist 
rimonabant (Moreira et al., 2008). By contrast, transgenic mice 
lacking expression of the CB1 receptor demonstrate an anxiogenic 
profile in the EPM, the light–dark box, open-field arena, and 
social interaction test (Haller et al., 2002, 2004; Maccarrone et al., 
2002; Martin et al., 2002; Urigüen et al., 2004) and demonstrate 
impaired stress coping behavior in the forced swim test (Steiner 
et al., 2008). Similarly, CB1 receptor antagonists increase anxiety-
related behaviors in the EPM (Patel and Hillard, 2006). Taken 
together, these studies suggest that eCBs act at CB1 receptors to 
reduce anxiety.
role of the endocannabInoId system In condItIoned fear and 
anxIety
Understanding the role of the eCB system in conditioned fear and 
aversive memories is important because a number of anxiety dis-
orders, including PTSD and phobias, are thought to result from 
dysregulated fear neurocircuitry (Rauch et al., 2006). Investigators 
have examined the effect of CB1 receptor agonists and antagonists 
on contextual and cue fear conditioning. Results from these studies 
were somewhat mixed. In rats, systemic injections of the CB1 recep-
tor antagonist AM251 enhance both the acquisition and expression 
of cue fear conditioning (Arenos et al., 2006; Reich et al., 2008). 
Administering AM251 (5 mg/kg, i.p) during tone–footshock con-
ditioning enhances acquisition of freezing behavior for both trace 
fear conditioning (hippocampal-dependent) and delay fear con-
ditioning (amygdala-dependent; Reich et al., 2008). Recently, we 
used an inhibitory avoidance task and found that microinjecting 
AM251 (6 ng) into the BLA significantly enhances conditioned 
avoidance but has no effect on conditioning when microinjected 
into the hippocampal CA1 area (Ganon-Elazar and Akirav, 2009; 
Abush and Akirav, 2010). However, others have shown that mice 
lacking the CB1 receptor or systemically administered with the CB1 
receptor antagonist AM251 (0.3–3 mg/kg) 30 min before behavioral 
testing show no contextually induced fear response (Mikics et al., 
2006). Furthermore, the CB1 receptor antagonist rimonabant or 
genetic deletion of the CB1 receptor has no effect on the acquisi-
tion of cue and context fear conditioning in mice (Marsicano et al., 
2002; Suzuki et al., 2004). On the other hand, cue-fear-potentiated 
startle is decreased by medial PFC injections of the CB1 receptor 
agonist WIN 55212-2 or the FAAH inhibitor URB597 (Lin et al., 
2008, 2009) and contextual fear conditioning is decreased by dor-
solateral periaqueductal gray injections of either anandamide or 
Frontiers in Behavioral Neuroscience  www.frontiersin.org  June 2011  | Volume 5  |  Article 34  |  7
Akirav  Cannabinoids effects on hippocampal memoryreferences
Abush, H., and Akirav, I. (2010). 
Cannabinoids modulate hippocampal 
memory and plasticity. Hippocampus 
20, 1126–1138.
Arenos, J. D., Musty, R. E., and Bucci, D. J. 
(2006). Blockade of cannabinoid CB1 
receptors alters contextual learning 
and memory. Eur. J. Pharmacol. 539, 
177–183.
Bambico, F. R., Katz, N., Debonnel, G., and 
Gobbi, G. (2007). Cannabinoids elicit 
antidepressant-like behavior and acti-
vate serotonergic neurons through the 
medial prefrontal cortex. J. Neurosci. 
27, 11700–11711.
Barad, M., Gean, P. W., and Lutz, B. 
(2006). The role of the amygdala in 
the extinction of conditioned fear. 
Biol. Psychiatry 60, 322–328.
Begg, M., Pacher, P., Bátkai, S., Osei-
Hyiaman, D., Offertáler, L., Mo, F. M., 
Liu, J., and Kunos, G. (2005). Evidence 
for novel cannabinoid receptors. 
Pharmacol. Ther. 106, 133–145.
Behr, J., Wozny, C., Fidzinski, P., and 
Schmitz, D. (2009). Synaptic plastic-
ity in the subiculum. Prog. Neurobiol. 
89, 334–342.
Berrendero, F., and Maldonado, R. 
(2002). Involvement of the opioid 
system in the anxiolytic-like effects 
induced by G9-tetrahydrocannabinol. 
Psychopharmacology (Berl.) 163, 
111–117.
Bielsky, I. F., and Young, L. J. (2004). 
Oxytocin, vasopressin, and social 
recognition in mammals. Peptides 25, 
1565–1574.
Bisogno, T., Howell, F., Williams, G., 
Minassi, A., Cascio, M. G., Ligresti, A., 
Matias, I., Schiano-Moriello, A., Paul, 
P., Williams, E. J., Gangadharan, U., 
Hobbs, C., Di Marzo, V., and Doherty, 
P. (2003). Cloning of the first sn1-DAG 
lipases points to the spatial and tem-
poral regulation of endocannabinoid 
signaling in the brain. J. Cell Biol. 163, 
463–468.
Bitencourt, R. M., Pamplona, F. A., and 
Takahashi, R. N. (2008). Facilitation 
of contextual fear memory extinction 
and anti-anxiogenic effects of AM404 
and cannabidiol in conditioned rats. 
Eur. Neuropsychopharmacol. 18, 
849–859.
Bliss, T. V., and Gardner-Medwin, A. R. 
(1973). Long-lasting potentiation of 
synaptic transmission in the dentate 
area of the unanaesthetized rabbit 
following stimulation of the perforant 
path. J. Physiol. 232, 357–374.
Bliss, T. V., and Lomo, T. (1973). Long-
lasting potentiation of synaptic 
transmission in the dentate area of 
the anaesthetized rabbit following 
stimulation of the perforant path. J. 
Physiol. 232, 331–356.
Bohme, G. A., Laville, M., Ledent, C., 
Parmentier, M., and Imperato, A. 
(2000). Enhanced long-term poten-
tiation in mice lacking cannabinoid 
CB1 receptors. Neuroscience 95, 5–7.
Bortolato, M., Campolongo, P., Mangieri, 
R. A., Scattoni, M. L., Frau, R., Trezza, 
V., La Rana, G., Russo, R., Calignano, A., 
Gessa, G. L., Cuomo, V., and Piomelli, 
D. (2006). Anxiolytic-like properties of 
the anandamide transport inhibitor 
AM404. Neuropsychopharmacology 31, 
2652–2659.
Bouton, M. E., Westbrook, R. F., Corcoran, 
K. A., and Maren, S. (2006). Contextual 
and temporal modulation of extinc-
tion: behavioral and biological mecha-
nisms. Biol. Psychiatry 60, 352–360.
Bremner, J. D., Randall, P., Scott, T. M., 
Bronen, R. A., Seibyl, J. P., Southwick, 
S. M., Delaney, R. C., McCarthy, 
G., Charney, D. S., and Innis, R. B. 
(1995). MRI-based measurement 
of hippocampal volume in patients 
with combat-related posttraumatic 
stress disorder. Am. J. Psychiatry 152, 
973–981.
Brodkin, J., and Moerschbaecher, J. 
M. (1997). SR141716A antago-
nizes the disruptive effects of can-
nabinoid ligands on learning in 
rats. J. Pharmacol. Exp. Ther. 282, 
1526–1532.
Charney, D. S., Deutch, A. Y., Krystal, J. 
H., Southwick, S. M., and Davis, M. 
(1993). Psychobiologic mechanisms 
of posttraumatic stress disorder. Arch. 
Gen. Psychiatry 50, 294–305.
Chevaleyre, V., Takahashi, K. 
A., and Castillo, P. E. (2006). 
Endocannabinoid-mediated synap-
tic plasticity in the CNS. Annu. Rev. 
Neurosci. 29, 37–76.
Chhatwal, J. P., Myers, K. M., Ressler, K. 
J., and Davis, M. (2005). Regulation of 
gephyrin and GABAA receptor bind-
ing within the amygdala after fear 
acquisition and extinction. J. Neurosci. 
25, 502–506.
Chhatwal, J. P., and Ressler, K. J. (2007). 
Modulation of fear and anxiety by the 
endogenous cannabinoid system. CNS 
Spectr. 12, 211–220.
Collins, D. R., Pertwee, R. G., and Davies, 
S. N. (1994). The action of synthetic 
cannabinoids on the induction of 
long-term potentiation in the rat 
hippocampal slice. Eur. J. Pharmacol. 
11, R7–R8.
Collins, D. R., Pertwee, R. G., and Davies, 
S. N. (1995). Prevention by the can-
nabinoid antagonist, SR141716A, 
of cannabinoid-mediated blockade 
of long-term potentiation in the rat 
hippocampal slice. Br. J. Pharmacol. 
115, 869–870.
Da, S., and Takahashi, R. N. (2002). SR 
141716A prevents delta 9-tetrahydro-
cannabinol-induced spatial learning 
deficit in a Morris-type water maze 
in mice. Prog. Neuropsychopharmacol. 
Biol. Psychiatry 26, 321–325.
Davies, S. N., Pertwee, R. G., and Riedel, 
G. (2002). Functions of cannabi-
noid receptors in the hippocampus. 
Neuropharmacology 42, 993–1007.
De Kloet, E. R., Joëls, M., and Holsboer, 
F. (2005). Stress and the brain: from 
adaptation to disease. Nat. Rev. 
Neurosci. 6, 463–475.
de Oliveira Alvares, L., de Oliveira, L. F., 
Camboim, C., Diehl, F., Genro, B. P., 
Lanziotti, V. B., and Quillfeldt, J. A. 
(2005). Amnestic effect of intrahip-
pocampal AM251, a CB1-selective 
blocker, in the inhibitory avoidance, 
but not in the open field habituation 
task, in rats. Neurobiol. Learn. Mem. 
83, 119–124.
de Oliveira Alvares, L., Genro, B. P., Vaz 
Breda, R., Pedroso, M. F., Da Costa, J. 
C., and Quillfeldt, J. A. (2006). AM251, 
a selective antagonist of the CB1 recep-
tor, inhibits the induction of long-term 
potentiation and induces retrograde 
amnesia in rats. Brain Res. 1075, 60–67.
Devane, W. A., Hanus, L., Breuer, A., 
Pertwee, R. G., Stevenson, L. A., 
Griffin, G., Gibson, D., Mandelbaum, 
A., Etinger, A., and Mechoulam, R. 
(1992). Isolation and structure of a 
brain constituent that binds to the 
cannabinoid receptor. Science 258, 
1946–1949.
Di Marzo, V. (2008). Endocannabinoids: 
synthesis and degradation. Rev. 
Physiol. Biochem. Pharmacol. 160, 
1–24.
summary
The findings demonstrate that the cannabinoid system has diverse 
effects on hippocampal memory and plasticity that cannot be cat-
egorized simply into an impairing or an enhancing effect, but are 
rather dependent on important variables such as the nature of 
the task (i.e., aversive, emotional or not), the memory stage under 
investigation (acquisition, consolidation, retrieval, extinction), and 
the brain areas involved.
The involvement of the eCB system in multiple aspects of brain 
function provides new targets for the development of novel thera-
peutic agents for a wide range of psychiatric disorders, including the 
treatment of anxiety disorders. Studies examining the involvement 
of cannabinoids in memory processes advance our understanding 
of the potential harmful consequences of cannabis use and the 
mechanisms underlying the close relationship between cannabi-
noids and cognition. This will help in determining whether the 
clinical benefits of using cannabinoids outweigh the risks, and to 
better cope with the deficits induced by cannabinoids.
receptor is expressed in diverse brain structures of relevance to 
psychiatric disorders and is mainly located presynaptically where 
it can suppress the release of other neurotransmitters (Marsicano 
and Lutz, 1999, 2006; Mackie, 2005). These neurotransmitters 
include the main inhibitory neurotransmitter GABA, the main 
excitatory neurotransmitter glutamate, as well as acetylcholine, 
noradrenaline, and serotonin (Katona et al., 1999; Harkany et al., 
2005; Monory et al., 2006; Häring et al., 2007; Oropeza et al., 
2007). Thus, synthetic compounds delivered systemically lack 
both the spatial and temporal specificity of endogenous com-
pounds (Lafene ˆtre et al., 2007; Viveros et al., 2007; Moreira and 
Lutz, 2008). This may explain not only the bell-shaped relation-
ship between dose and effect that some studies have observed, 
but also why elevation of eCB levels sometimes has effects that 
are different from those observed with exogenous cannabinoids. 
Finally, the diversity of eCB ligands with their multiple synthetic 
and degradation pathways adds a further level of complexity to 
the eCB system (Di Marzo, 2008).
Frontiers in Behavioral Neuroscience  www.frontiersin.org  June 2011  | Volume 5  |  Article 34  |  8
Akirav  Cannabinoids effects on hippocampal memorythe   hippocampus and cerebellum. J. 
Neurosci. 26, 2991–3001.
Kogan, J. H., Frankland, P. W., and Silva, A. 
J. (2000). Long-term memory under-
lying hippocampus-dependent social 
recognition in mice. Hippocampus 10, 
47–56.
Kogan, N., and Mechoulam, R. (2006). 
The chemistry of endocannabinoids. 
J. Endocrinol. Invest. 29, 3–14.
Lafene ˆtre, P., Chaouloff, F., and Marsicano, 
G. (2007). The endocannabinoid sys-
tem in the processing of anxiety and 
fear and how CB1 receptors may 
modulate fear extinction. Pharmacol. 
Res. 56, 367–381.
LeDoux, J. (2003). The emotional brain, 
fear, and the amygdala. Cell. Mol. 
Neurobiol. 23, 727–738.
Lichtman, A. H., Dimen, K. R., and 
Martin, B. R. (1995). Systemic or intra-
hippocampal cannabinoid adminis-
tration impairs spatial memory in rats. 
Psychopharmacology 119, 282–290.
Lichtman, A. H., and Martin, B. R. 
(1996). Delta 9-tetrahydrocannabi-
nol impairs spatial memory through 
a cannabinoid receptor mechanism. 
Psychopharmacology (Berl.) 126, 
125–131.
Lin, H. C., Mao, S. C., Chen, P. S., and 
Gean, P. (2008). Chronic cannabinoid 
administration in vivo compromises 
extinction of fear memory. Learn. 
Mem. 15, 876–884.
Lin, H. C., Mao, S. C., Su, C. L., and Gean, 
P. W. (2009). The role of prefrontal 
cortex CB1 receptors in the modula-
tion of fear memory. Cereb. Cortex 19, 
165–175.
Linszen, D., and van Amelsvoort, T. 
(2007). Cannabis and psychosis: 
an update on course and biological 
plausible mechanisms. Curr. Opin. 
Psychiatry 20, 116–120.
Lutz, B. (2007). The endocannabinoid 
system and extinction learning. Mol. 
Neurobiol. 36, 92–101.
Lutz, B. (2009). Endocannabinoid signals 
in the control of emotion. Curr. Opin. 
Pharmacol. 9, 46–52.
Maccarrone, M., Valverde, O., Barbaccia, 
M. L., Castañé, A., Maldonado, R., 
Ledent, C., Parmentier, M., and 
Finazzi-Agrò, A. (2002). Age-related 
changes of anandamide metabolism in 
CB1 cannabinoid receptor knockout 
mice: correlation with behaviour. Eur. 
J. Neurosci. 15, 1178–1186.
Mackie, K. (2005). Distribution of can-
nabinoid receptors in the central and 
peripheral nervous system. Handb. 
Exp Pharmacol. 168, 299–325.
Mallet, P. E., and Beninger, R. J. (1998). 
The cannabinoid CB1 receptor 
antagonist SR141716A attenuates 
the memory impairment produced 
by delta-9-tetrahydrocannabinol or 
Hill, M. N., Patel, S., Campolongo, P., 
Tasker, J. G., Wotjak, C. T., and Bains, 
J. S. (2010). Functional interactions 
between stress and the endocannabi-
noid system: from synaptic signaling 
to behavioral output. J. Neurosci. 10, 
14980–14986.
Hoffman, A. F., and Lupica, C. R. (2000). 
Mechanisms of cannabinoid inhibi-
tion of GABA(A) synaptic transmis-
sion in the hippocampus. J. Neurosci. 
20, 2470–2479.
Hoffman, A. F., Oz, M., Caulder, T., and 
Lupica, C. R. (2003). Functional tol-
erance and blockade of long-term 
depression at synapses in the nucleus 
accumbens after chronic cannabinoid 
exposure. J. Neurosci. 23, 4815–4820.
Hoffman, A. F., Oz, M., Yang, R., 
Lichtman, A. H., and Lupica, C. R. 
(2007). Opposing actions of chronic 
{Delta} 9-tetrahydrocannabinol and 
cannabinoid antagonists on hip-
pocampal long-term potentiation. 
Learn. Mem. 14, 63–74.
Hölter, S. M., Kallnik, M., Wurst, W., 
Marsicano, G., Lutz, B., and Wotjak, C. 
T. (2005). Cannabinoid CB1 receptor 
is dispensable for memory extinction 
in an appetitively-motivated learning 
task. Eur. J. Pharmacol. 510, 69–74.
Joëls, M., and Baram, T. Z. (2009). The 
neuro-symphony of stress. Nat. Rev. 
Neurosci. 10, 459–466.
Kathuria, S., Gaetani, S., Fegley, D., Valiño, 
F., Duranti, A., Tontini, A., Mor, M., 
Tarzia, G., La Rana, G., Calignano, A., 
Giustino, A., Tattoli, M., Palmery, M., 
Cuomo, V., and Piomelli, D. (2003). 
Modulation of anxiety through block-
ade of anandamide hydrolysis. Nat. 
Med. 9, 76–81.
Katona, I., Rancz, E. A., Acsády, L., Ledent, 
C., Mackie, K., Hajos, N., and Freund, 
T. F. (2001). Distribution of CB1 
cannabinoid receptors in the amyg-
dala and their role in the control of 
GABAergic transmission. J. Neurosci. 
21, 9506–9518.
Katona, I., Sperlagh, B., Sik, A., Kafalvi, 
A., Vizi, E. S., Mackie, K., and Freund, 
T. F. (1999). Presynaptically located 
CB1 cannabinoid receptors regulate 
GABA release from axon terminals of 
specific hippocampal interneurons. J. 
Neurosci.19, 4544–4558.
Katona, I., Urban, G. M., Wallace, M., 
Ledent, C., Jung, K. M., Piomelli, D., 
Mackie, K., and Freund, T. F. (2006). 
Molecular composition of the endo-
cannabinoid system at glutamatergic 
synapses. J. Neurosci. 26, 5628–5637.
Kawamura, Y., Fukaya, M., Maejima, 
T., Yoshida, T., Miura, E., Watanabe, 
M., Ohno-Shosaku, T., and Kano, M. 
(2006). The CB1 cannabinoid recep-
tor is the major cannabinoid recep-
tor at excitatory presynaptic sites in 
Haller, J., Bakos, N., Szirmay, M., Ledent, 
C., and Freund, T. (2002). The effects 
of genetic and pharmacological 
blockade of the CB1 cannabinoid 
receptor on anxiety. Eur. J. Neurosci. 
16, 1395–1398.
Haller, J., Varga, B., Ledent, C., Barna, 
I., and Freund, T. (2004). Context-
dependent effects of CB1 cannabi-
noid gene disruption on anxiety-like 
and social behaviour in mice. Eur. J. 
Neurosci. 19, 1906–1912.
Hampson, R. E., and Deadwyler, S. A. 
(1999). Cannabinoids, hippocampal 
function and memory. Life Sci. 65, 
715–723.
Hampson, R. E., and Deadwyler, S. A. 
(2000). Cannabinoids reveal the 
necessity of hippocampal neural 
encoding for short-term memory in 
rats. J. Neurosci. 20, 8932–8942.
Häring, M., Marsicano, G., Lutz, B., and 
Monory, K. (2007). Identification of 
the cannabinoid receptor type 1 in 
serotonergic cells of raphe nuclei in 
mice. Neuroscience 146, 1212–1219.
Harkany, T., Dobszay, M., Cayetanot, F., 
Härtig, W., Siegemund, T., Aujard, F., 
and Mackie, K. (2005). Redistribution 
of CB1 cannabinoid receptors dur-
ing evolution of cholinergic basal 
forebrain territories and their cor-
tical projection areas: A compari-
son between the gray mouse lemur 
(microcebus murinus, primates) and 
rat. Neuroscience 135, 595–609.
Herkenham, M., Lynn, A. B., Johnson, M. 
R., Melvin, L. S., de Costa, B. R., and 
Rice, K. C. (1991). Characterization 
and localization of cannabinoid recep-
tors in rat brain: a quantitative in vitro 
autoradiographic study. J. Neurosci. 11, 
563–583.
Herkenham, M., Lynn, A. B., Little, M. 
D., Johnson, M. R., Melvin, L. S., de 
Costa, B. R., and Rice, K. C. (1990). 
Cannabinoid receptor localization in 
brain. Proc. Natl. Acad. Sci. U.S.A. 87, 
1932–1936.
Heyser, C. J., Hampson, R. E., and 
Deadwyler, S. A. (1993). Effects of 
∆9-tetrahydrocannabinol on delayed 
match to sample performance in rats: 
alterations in short-term memory 
associated with changes in task spe-
cific firing of hippocampal cells. J. 
Pharmacol. Exp. Ther. 264, 294–307.
Hill, M. N., and Gorzalka, B. B. (2009). 
The endocannabinoid system and 
the treatment of mood and anxiety 
disorders. CNS Neurol. Disord. Drug 
Targets 8, 451–458.
Hill, M. N., Karacabeyli, E. S., and 
Gorzalka, B. B. (2007). Estrogen 
recruits the endocannabinoid 
system to modulate emotional-
ity. Psychoneuroendocrinology  32, 
350–357.
Egashira, N., Mishima, K., Iwasaki, K., 
and Fujiwara, M. (2002). Intracerebral 
microinjections of delta 9-tetrahydro-
cannabinol: search for the impairment 
of spatial memory in the eight-arm 
radial maze in rats. Brain Res. 952, 
239–245.
Fanselow, M. S. (1998). Pavlovian con-
ditioning, negative feedback, and 
blocking: mechanisms that regulate 
association formation. Neuron 20, 
625–627.
Ferguson, J. N., Aldag, J. M., Insel, T. R., 
and Young, L. J. (2001). Oxytocin in 
the medial amygdala is essential for 
social recognition in the mouse. J. 
Neurosci. 21, 278–8285.
Ferrari, F., Ottani, A., Vivoli, R., and 
Giuliani, D. (1999). Learning impair-
ment produced in rats by the cannabi-
noid agonist HU 210 in a water-maze 
task. Pharmacol. Biochem. Behav. 64, 
555–561.
Finn, D., Beckett, S., Richardson, D., 
Kendall, D., Marsden, C., and 
Chapman, V. (2004). Evidence for dif-
ferential modulation of conditioned 
aversion and fear-conditioned analge-
sia by CB1 receptors. Eur. J. Neurosci. 
20, 848–852.
Freund, T. F., Katona, I., and Piomelli, D. 
(2003). Role of endogenous cannabi-
noids in synaptic signaling. Physiol. 
Rev. 83, 1017–1066.
Galiegue, S., Mary, S., Marchand, J., 
Dussossoy, D., Carrière, D., Carayon, 
P., Bouaboula, M., Shire, D., Le Fur, 
G., and Casellas, P. (1995). Expression 
of central and peripheral cannabinoid 
receptors in human immune tissues 
and leukocyte subpopulations. Eur. J. 
Biochem. 232, 54–61.
Ganon-Elazar, E., and Akirav, I. (2009). 
Cannabinoid receptor activation in 
the basolateral amygdala blocks the 
effects of stress on the conditioning 
and extinction of inhibitory avoid-
ance. J. Neurosci. 29, 11078–11088.
Gaoni, Y., and Mechoulam, R. (1964). 
Isolation, structure, and partial 
synthesis of an active constituent 
of hashish. J. Am. Chem. Soc. 86, 
1646–1647.
Gorzalka, B. B., Hill, M. N., and Hillard, 
C. J. (2008). Regulation of endocan-
nabinoid signaling by stress: impli-
cations for stress-related affective 
disorders. Neurosci. Biobehav. Rev. 32, 
1152–1160.
Hajos, N., Katona, I., Naiem, S., MacKie, 
K., Ledent, C., Mody, I., and Freund, 
T. (2000). Cannabinoids inhibit hip-
pocampal GABAergic transmission 
and network oscillations. Eur. J. 
Neurosci. 12, 3239–1349.
Hall, W., and Solowij, N. (1998). Adverse 
effects of cannabis. Lancet  352, 
1611–1616.
Frontiers in Behavioral Neuroscience  www.frontiersin.org  June 2011  | Volume 5  |  Article 34  |  9
Akirav  Cannabinoids effects on hippocampal memoryPatel, S., and Hillard, C. J. (2006). 
Pharmacological evaluation of can-
nabinoid receptor ligands in a mouse 
model of anxiety: further evidence for 
an anxiolytic role for endogenous can-
nabinoid signaling. J. Pharmacol. Exp. 
Ther. 318, 304–311.
Phelps, E. A., Delgado, M. R., Nearing, K. 
I., and LeDoux, J. E. (2004). Extinction 
learning in humans: role of the amyg-
dala and vmPFC. Neuron 43, 897–905.
Pitman, R. K., Gilbertson, M. W., Gurvits, 
T. V., May, F. S., Lasko, N. B., Metzger, 
L. J., Shenton, M. E., Yehuda, R., Orr, S. 
P., and Harvard/VA PTSD Twin Study 
Investigators. (2006). Clarifying the 
origin of biological abnormalities in 
PTSD through the study of identical 
twins discordant for combat exposure. 
Ann. N. Y. Acad. Sci. 1071, 242–254.
Quirk, G. J., Garcia, R., and González-
Lima, F. (2006). Prefrontal mecha-
nisms in extinction of conditioned 
fear. Biol. Psychiatry 60, 337–343.
Rauch, S. L., Shin, L. M., and Phelps, E. 
A. (2006). Neurocircuitry models of 
posttraumatic stress disorder and 
extinction: human neuroimaging 
research – past, present, and future. 
Biol. Psychiatry 60, 376–382.
Reich, C. G., Mohammadi, M. H., and 
Alger, B. E. (2008). Endocannabinoid 
modulation of fear responses: learn-
ing and state-dependent perfor-
mance effects. J. Psychopharmacol. 
22, 769–777.
Resstel, L. B. M., Lisboa, S., Aguiar, D., 
Corrêa, F. M. A., and Guimaraes, F. 
(2008). Activation of CB1 cannabi-
noid receptors in the dorsolateral 
periaqueductal gray reduces the 
expression of contextual fear condi-
tioning in rats. Psychopharmacology 
(Berl.) 198, 405–411.
Ribeiro, A., Ferraz-de-Paula, V., Pinheiro, 
M., and Palermo-Neto, J. (2009). 
Dose-response effects of systemic 
anandamide administration in mice 
sequentially submitted to the open 
field and elevated plus-maze tests. 
Braz. J. Med. Biol. Res. 42, 556–560.
Riedel, G., and Davies, S. N. (2005). 
Cannabinoid function in learning, 
memory and plasticity. Handb. Exp. 
Pharmacol. 168, 445–477.
Robinson, L., Hinder, L., Pertwee, R. 
G., and Riedel, G. (2003). Effects of 
delta-9-THC and WIN 55,212-2 on 
place preference in the water maze in 
rats. Psychopharmacology (Berl.) 166, 
40–50.
Rodriguez de Fonseca, F., Rubio, P., 
Menzaghi, F., Merlo-Pich, E., Rivier, 
J., Koob, G. F., and Navarro, M. (1996). 
Corticotropin-releasing factor (CRF) 
antagonist [D-Phe12, Nle21, 38, C 
alpha MeLeu37] CRF attenuates the 
acute actions of the highly potent 
the CB 1 receptor antagonist rimona-
bant on extinction learning in mice 
are task-specific. Psychopharmacology 
(Berl.) 191, 223–231.
Nowicky, A. V., Teyler, T. J., and Vardaris, 
R. M. (1987). The modulation of 
long term potentiation by delta-
9-tetrahydrocannabinol in the rat 
hippocampus, in vitro. Brain Res. Bull. 
19, 663–672.
Nyíri, G., Cserép, C., Szabadits, E., Mackie, 
K., and Freund, T. F. (2005). CB1 can-
nabinoid receptors are enriched in 
the perisynaptic annulus and on pre-
terminal segments of hippocampal 
GABAergic axons. Neuroscience 136, 
811–822.
Ohno-Shosaku, T., Maejima, T., and 
Kano, M. (2001). Endogenous can-
nabinoids mediate retrograde signals 
from depolarized postsynaptic neu-
rons to presynaptic terminals. Neuron 
29, 729–738.
Okamoto, Y., Morishita, J., Tsuboi, 
K., Tonai, T., and Ueda, N. (2004). 
Molecular characterization of a phos-
pholipase D generating anandamide 
and its congeners. J. Biol. Chem. 279, 
5298–5305.
Onaivi, E., Green, M., and Martin, B. 
(1990). Pharmacological characteri-
zation of cannabinoids in the elevated 
plus maze. J. Pharmacol. Exp. Ther. 
253, 1002–1009.
Onaivi, E. S., Ishiguro, H., Gong, J.-P., 
Patel, S., Perchuk, A., Meozzi, P. A., 
Myers, L., Mora, Z., Tagliaferro, P., 
Gardner, E., Brusco, A., Akinshola, 
B. E., Liu, Q. R., Hope, B., Iwasaki, S., 
Arinami, T., Teasenfitz, L., and Uhl, G. 
R. (2006). Discovery of the presence 
and functional expression of cannabi-
noid CB2 receptors in brain. Ann. N. 
Y. Acad. Sci. 1074, 514–536.
Oropeza, V. C., Mackie, K., and Van 
Bockstaele, E. J. (2007). Cannabinoid 
receptors are localized to noradren-
ergic axon terminals in the rat frontal 
cortex. Brain Res. 1127, 36–44.
O’Shea, M., Singh, M. E., McGregor, I. S., 
and Mallet, P. E. (2004). Chronic can-
nabinoid exposure produces lasting 
memory impairment and increased 
anxiety in adolescent but not adult 
rats. J. Psychopharmacol. 18, 502–508.
Pamplona, F. A., Bitencourt, R. M., and 
Takahashi, R. N. (2008). Short-and 
long-term effects of cannabinoids 
on the extinction of contextual fear 
memory in rats. Neurobiol. Learn. 
Mem. 90, 290–293.
Pamplona, F. A., Prediger, R. D. S., Pandolfo, 
P., and Takahashi, R. N. (2006). The 
cannabinoid receptor agonist WIN 
55,212-2 facilitates the extinction of 
contextual fear memory and spatial 
memory in rats. Psychopharmacology 
(Berl.) 188, 641–649.
Milad, M. R., and Quirk, G. J. (2002). 
Neurons in medial prefrontal cortex 
signal memory for fear extinction. 
Nature 420, 70–74.
Milad, M. R., Rauch, S. L., Pitman, R. K., 
and Quirk, G. J. (2006). Fear extinction 
in rats: implications for human brain 
imaging and anxiety disorders. Biol. 
Psychol. 73, 61–71.
Mishima, K., Egashira, N., Hirosawa, 
N., Fujii, M., Matsumoto, Y., 
Iwasaki, K., and Fujiwara, M. (2001). 
Characteristics of learning and mem-
ory impairment induced by delta9-
tetrahydrocannabinol in rats. Jpn. J. 
Pharmacol. 87, 297–308.
Misner, D. L., and Sullivan, J. M. (1999). 
Mechanism of cannabinoid effects on 
long-term potentiation and depres-
sion in hippocampal CA1 neurons. J. 
Neurosci. 19, 6795–6805.
Moise, A. M., Eisenstein, S. A., Astarita, 
G., Piomelli, D., and Hohmann, A. G. 
(2008). An endocannabinoid signal-
ing system modulates anxiety-like 
behavior in male syrian hamsters. 
Psychopharmacology (Berl.) 200, 
333–346.
Monory, K., Massa, F., Egertová, M., Eder, 
M., Blaudzun, H., Westenbroek, R., 
Kelsch, W., Jacob, W., Marsch, R., 
Ekker, M., Long, J., Rubenstein, J. L., 
Goebbels, S., Nave, K. A., During, M., 
Klugmann, M., Wölfel, B., Dodt, H. 
U., Zieglgänsberger, W., Wotjak, C. T., 
Mackie, K., Elphick, M. R., Marsicano, 
G., and Lutz, B. (2006). The endocan-
nabinoid system controls key epilep-
togenic circuits in the hippocampus. 
Neuron 51, 455–466.
Moreira, F. A., Aguiar, D. C., and 
Guimarães, F. S. (2007). Anxiolytic-
like effect of cannabinoids injected 
into the rat dorsolateral periaque-
ductal gray. Neuropharmacology 52, 
958–965.
Moreira, F. A., Kaiser, N., Monory, K., and 
Lutz, B. (2008). Reduced anxiety-like 
behaviour induced by genetic and 
pharmacological inhibition of the 
endocannabinoid-degrading enzyme 
fatty acid amide hydrolase (FAAH) 
is mediated by CB1 receptors. 
Neuropharmacology 54, 141–150.
Moreira, F. A., and Lutz, B. (2008). The 
endocannabinoid system: emotion, 
learning and addiction. Addict. Biol. 
13, 196–212.
Nakamura, E. M., da Silva, E. A., Concilio, 
G. V., Wilkinson, D. A., and Masur, J. 
(1991). Reversible effects of acute 
and long-term administration of 
∆9-tetrahydrocannabinol (THC) 
on memory in the rat. Drug Alcohol 
Depend. 28, 167–175.
Niyuhire, F., Varvel, S. A., Thorpe, A. J., 
Stokes, R. J., Wiley, J. L., and Lichtman, 
A. H. (2007). The disruptive effects of 
anandamide. Psychopharmacology 
140, 11–19.
Maren, S., and Quirk, G. J. (2004). 
Neuronal signalling of fear memory. 
Nat. Rev. Neurosci. 5, 844–852.
Marsch, R., Foeller, E., Rammes, G., 
Bunck, M., Kossl, M., Holsboer, F., 
Zieglgänsberger, W., Landgraf, R., 
Lutz, B., and Wotjak, C. T. (2007). 
Reduced anxiety, conditioned fear, and 
hippocampal long-term potentiation 
in transient receptor potential vanil-
loid type 1 receptor-deficient mice. J. 
Neurosci. 27, 832–839.
Marsicano, G., and Lutz, B. (1999). 
Expression of the cannabinoid 
receptor CB1 in distinct neuronal 
subpopulations in the adult mouse 
forebrain.  Eur. J. Neurosci. 11, 
4213–4225.
Marsicano, G., and Lutz, B. (2006). 
Neuromodulatory functions of 
the endocannabinoid system. J. 
Endocrinol. Invest. 29, 27–46.
Marsicano, G., Wotjak, C. T., Azad, S. C., 
Bisogno, T., Rammes, G., Cascio, M. 
G., Hermann, H., Tang, J., Hofmann, 
G., Zieglansberger, W., Di Marzo, V., 
and Lutz, B. (2002).The endogenous 
cannabinoid system controls extinc-
tion of aversive memories. Nature 418, 
530–534.
Martin, M., Ledent, C., Parmentier, M., 
Maldonado, R., and Valverde, O. 
(2002). Involvement of CB1 cannabi-
noid receptors in emotional behav-
iour. Psychopharmacology (Berl.) 159, 
379–387.
Matsuda, L. A., Lolait, S. J., Brownstein, 
M. J., Young, A. C., and Bonner, T. I. 
(1990). Structure of a cannabinoid 
receptor and functional expression 
of the cloned cDNA. Nature 346, 
561–564.
McEwen, B. C., and Gould, E. (1990). 
Adrenal steroid influences on the 
survival of hippocampal neurons. 
Biochem. Pharmacol. 40, 2393–2402.
McEwen, B. S. (1999). Stress and hip-
pocampal plasticity. Annu. Rev. 
Neurosci. 22, 105–122.
Meaney, M. J. (2001). Maternal care, gene 
expression, and the transmission of 
individual differences in stress reac-
tivity across generations. Neuroscience 
24, 1161–1192.
Mikics, É., Dombi, T., Barsvári, B., Varga, 
B., Ledent, C., Freund, T. F., and Haller, 
J. (2006). The effects of cannabinoids 
on contextual conditioned fear in 
CB1 knockout and CD1 mice. Behav. 
Pharmacol. 17, 223–230.
Milad, M. R., Orr, S. P., Lasko, N. B., 
Chang, Y., Rauch, S. L., and Pitman, 
R. K. (2008). Presence and acquired 
origin of reduced recall for fear extinc-
tion in PTSD: results of a twin study. 
J. Psychiatr. Res. 42, 515–520.
Frontiers in Behavioral Neuroscience  www.frontiersin.org  June 2011  | Volume 5  |  Article 34  |  10
Akirav  Cannabinoids effects on hippocampal memoryViveros, M., Marco, E., Llorente, R., 
and Lopez-Gallardo, M. (2007). 
Endocannabinoid system and synaptic 
plasticity: implications for emotional 
responses. Neural Plast. 2007, 52908.
Viveros, M., Marco, E. M., and File, S. 
E. (2005). Endocannabinoid system 
and stress and anxiety responses. 
Pharmacol. Biochem. Behav. 81, 
331–342.
Wegener, N., Kuhnert, S., Thuns, A., 
Roese, R., and Koch, M. (2008). 
Effects of acute systemic and intra-
cerebral stimulation of cannabinoid 
receptors on sensorimotor gating, 
locomotion and spatial memory in 
rats. Psychopharmacology (Berl.) 198, 
375–385.
Wessa, M., and Flor, H. (2007). Failure of 
extinction of fear responses in post-
traumatic stress disorder: evidence 
from second-order conditioning. Am. 
J. Psychiatry 164, 1684–1692.
Woon, F. L., and Hedges, D. W. (2008). 
Hippocampal and amygdala volumes 
in children and adults with childhood 
maltreatment-related posttraumatic 
stress disorder: a meta-analysis. 
Hippocampus 18, 729–736.
Yim, T. T., Hong, N. S., Ejaredar, M., 
McKenna, J. E., and McDonald, R. 
J. (2008). Post-training CB1 can-
nabinoid receptor agonist activation 
disrupts long-term consolidation of 
spatial memories in the hippocampus. 
Neuroscience 151, 929–936.
Conflict of Interest Statement: The 
author declares that the research was 
conducted in the absence of any com-
mercial or financial relationships that 
could be construed as a potential conflict 
of interest.
Received: 26 May 2011; paper pending pub-
lished: 07 June 2011; accepted: 14 June 2011; 
published online: 23 June 2011.
Citation: Akirav I (2011) The role of can-
nabinoids in modulating emotional and 
non-emotional memory processes in the 
hippocampus. Front. Behav. Neurosci. 5:34. 
doi: 10.3389/fnbeh.2011.00034
Copyright © 2011 Akirav. This is an open-
access article subject to a non-exclusive 
license between the authors and Frontiers 
Media SA, which permits use, distribution 
and reproduction in other forums, provided 
the original authors and source are credited 
and other Frontiers conditions are complied 
with.
fear. J. Neuropsychiatry Clin. Neurosci. 
21, 108–113.
Terranova, J. P., Michaud, J. C., Le Fur, 
G., and Soubrie, P. (1995). Inhibition 
of long-term potentiation in rat hip-
pocampal slices by anandamide and 
WIN55212–2: reversal by SR141716 
A, a selective antagonist of CB1 
cannabinoid receptors. Naunyn 
Schmiedebergs Arch. Pharmacol. 352, 
576–579.
Tsou, K., Brown, S., Sanudo-Pena, M. C., 
Mackie, K., and Walker, J. M. (1998). 
Immunohistochemical distribution of 
cannabinoid CB1 receptors in the rat 
central nervous system. Neuroscience 
83, 393–411.
Urigüen, L., Pérez-Rial, S., Ledent, C., 
Palomo, T., and Manzanares, J. (2004). 
Impaired action of anxiolytic drugs 
in mice deficient in cannabinoid CB1 
receptors. Neuropharmacology 46, 
966–973.
Van den Berg, C. L., Hol, T., Van Ree, 
J. M., Spruijt, B. M., Everts, H., and 
Koolhaas, J. M. (1999). Play is indis-
pensable for an adequate development 
of coping with social challenges in the 
rat. Dev. Psychobiol. 34, 129–138.
Van Sickle, M. D., Duncan, M., Kingsley, P. 
J., Mouihate, A., Urbani, P., Mackie, K., 
Stella, N., Makriyannis, A., Piomelli, 
D., Davison, J. S., Marnett, L. J., 
Di Marzo, V., Pittman, Q. J., Patel, 
K. D., and Sharkey, K. A. (2005). 
Identification and functional charac-
terization of brainstem cannabinoid 
CB2 receptors. Science 310, 329–332.
Van Wimersma Greidanus, T. B., and 
Maigret, C. (1996). The role of limbic 
vasopressin and oxytocin in social 
recognition. Brain Res. 713, 153–159.
Varvel, S. A., Anum, E. A., and Lichtman, A. 
H. (2005). Disruption of CB1 receptor 
signaling impairs extinction of spatial 
memory in mice. Psychopharmacology 
(Berl.) 179, 863–872.
Varvel, S. A., Hamm, R. J., Martin, B. 
R., and Lichtman, A. H. (2001). 
Differential effects of delta9-THC on 
spatial reference and working memory 
in mice. Psychopharmacology (Berl.) 
157, 142–150.
Varvel, S. A., Wise, L. E., Niyuhire, F., 
Cravatt, B. F., and Lichtman, A. H. 
(2007). Inhibition of fatty-acid amide 
hydrolase accelerates acquisition and 
extinction rates in a spatial memory 
task. Neuropsychopharmacology 32, 
1032–1041.
  recurrent major depression. J. 
Neurosci. 19, 5034–5043.
Shen, M., Piser, T. M., Seybold, V. S., and 
Thayer, S. A. (1996). Cannabinoid 
receptor agonists inhibit glutamater-
gic synaptic transmission in rat hip-
pocampal cultures. J. Neurosci. 16, 
4322–4334.
Shin, L. M., and Liberzon, I. (2010). 
The neurocircuitry of fear, 
stress, and anxiety disorders. 
Neuropsychopharmacology  35, 
169–191.
Slanina, K. A., Roberto, M., and Schweitzer, 
P. (2005). Endocannabinoids restrict 
hippocampal long term potentia-
tion via CB1. Neuropharmacology 49, 
660–668.
Sokal, D. M., Benetti, C., Girlanda, E., and 
Large, C. H. (2008). The CB1 recep-
tor antagonist, SR141716A, prevents 
high-frequency stimulation-induced 
reduction of feedback inhibition in the 
rat dentate gyrus following perforant 
path stimulation in vivo. Brain Res. 
1223, 50–58.
Steiner, M. A., Marsicano, G., Nestler, E. J., 
Holsboer, F., Lutz, B., and Wotjak, C. 
T. (2008). Antidepressant-like behav-
ioral effects of impaired cannabinoid 
receptor type 1 signaling coincide with 
exaggerated corticosterone secretion 
in mice. Psychoneuroendocrinology 
33, 54–67.
Suenaga, T., and Ichitani, Y. (2008). Effects 
of hippocampal administration of a 
cannabinoid receptor agonist WIN 
55,212-2 on spontaneous object and 
place recognition in rats. Behav. Brain 
Res. 190, 248–252.
Suenaga, T., Kaku, M., and Ichitani, Y. 
(2008). Effects of intrahippocampal 
cannabinoid receptor agonist and 
antagonist on radial maze and T-maze 
delayed alternation performance in 
rats. Pharmacol. Biochem. Behav. 91, 
91–96.
Sullivan, J. M. (2000). Cellular and 
molecular mechanisms underlying 
learning and memory impairments 
produced by cannabinoids. Learn. 
Mem. 7, 132–139.
Suzuki, A., Josselyn, S. A., Frankland, P., 
Masushige, S., Silva, A. J., and Kida, S. 
(2004). Memory reconsolidation and 
extinction have distinct temporal and 
biochemical signatures. J. Neurosci. 24, 
4787–4795.
Taber, K. H., and Hurley, R. A. (2009). 
Endocannabinoids: stress, anxiety, and 
 cannabinoid receptor agonist HU-210 
on defensive-withdrawal behavior in 
rats. J. Pharmacol. Exp. Ther. 276, 
56–64.
Roohbakhsh, A., Moghaddam, A. H., 
Massoudi, R., and Zarrindast, M. R. 
(2007). Role of dorsal hippocampal 
cannabinoid receptors and nitric oxide 
in anxiety like behaviours in rats using 
the elevated plus-maze test. Clin. Exp. 
Pharmacol. Physiol. 34, 223–229.
Ross, R. A. (2003). Anandamide and 
vanilloid TRPV1 receptors. Br. J. 
Pharmacol. 140, 790–801.
Rothbaum, B. O., and Davis, M. (2003). 
Applying learning principles to the 
treatment of post-trauma reactions. 
Ann. N. Y. Acad. Sci. 1008, 112–121.
Rubino, T., Guidali, C., Vigano, D., Realini, 
N., Valenti, M., Massi, P., and Parolaro, 
D. (2008a). CB1 receptor stimulation 
in specific brain areas differently 
modulate anxiety-related behaviour. 
Neuropharmacology 54, 151–160.
Rubino, T., Realini, N., Castiglioni, C., 
Guidali, C., Viganó, D., Marras, E., 
Petrosino, S., Perletti, G., Maccarrone, 
M., Di Marzo, V., and Parolaro, D. 
(2008b). Role in anxiety behavior of 
the endocannabinoid system in the 
prefrontal cortex. Cereb. Cortex 18, 
1292–1301.
Sapolsky, R. M. (1996). Why stress is bad 
for your brain. Science 273, 749–750.
Schat, A. R., Lee, M., Condie, R. B., Pulaski, 
J. T., and Kaminski, N. E. (1997). 
Cannabinoid receptors CB1 and CB2: 
a characterization of expression and 
adenylate cyclase modulation within 
the immune system. Toxicol. Appl. 
Pharmacol. 142, 278–287.
Scherma, M., Medalie, J., Fratta, W., 
Vadivel, S. K., Makriyannis, A., 
Piomelli, D., Mikics, E., Haller, J., 
Yasar, S., Tanda, G., and Goldberg, S. R. 
(2008). The endogenous cannabinoid 
anandamide has effects on motivation 
and anxiety that are revealed by fatty 
acid amide hydrolase (FAAH) inhibi-
tion. Neuropharmacology 54, 129–140.
Segev, A., and Akirav, I. (2011). Differential 
effects of cannabinoid receptor agonist 
on social discrimination and contex-
tual fear in amygdala and hippocam-
pus. Learn. Mem. 18, 254–259.
Sheline, Y. I., Sanghavi, M., Mintun, 
M. A., and Gado, M. H. (1999). 
Depression duration but not age 
predicts hippocampal volume loss 
in medically healthy women with 
Frontiers in Behavioral Neuroscience  www.frontiersin.org  June 2011  | Volume 5  |  Article 34  |  11
Akirav  Cannabinoids effects on hippocampal memory